Veranova is a global leader in the development and manufacture of complex and specialty APIs, with decades of experience in ADC linker-payloads, bioconjugation, oligonucleotides, highly potent APIs (HPAPIs), and controlled substances.
Managing Complexity with Confidence: Veranova Supports Your New Modalities, HPAPIs, and Other Specialized APIs
Veranova is a global leader in the development and manufacture of complex active pharmaceutical ingredients (APIs), offering specialized expertise in antibody–drug conjugate (ADC) linker-payloads, bioconjugation, oligonucleotides, highly potent APIs (HPAPIs), controlled substances, and solid-form science:
- Veranova brings over 20 years of experience developing and manufacturing ADC linker-payloads, with deep knowledge of multiple ADC linker–payload systems and comprehensive services to support your project from early development through large-scale commercial manufacturing.
- Veranova is a leading manufacturer of controlled substances, HPAPIs, and generic APIs—with more than 50 years of experience, 200+ active drug master files (DMFs), and 2,500+ completed solid form projects.
Learn more about Veranova at CPHI Japan
Come see Veranova at booth 3B-03 at CPHI Japan! The team is ready to answer your questions about how Veranova’s experts can support the development and manufacture of your complex molecules.
You can also learn more about bioconjugates and sustainable supply in a talk from Cécile Maupas, Veranova’s Sr. Vice President and Chief Commercial Officer. Her presentation, “Transforming Bioconjugate Medications—Building out R&D and Commercial Facilities for Sustainable Supply in the U.S. Amid Current Global Dynamics,” takes place at 15:00 on Tuesday, April 21, at venue 2A.
Expanding Capacity for New Modalities
To meet growing demand, Veranova is expanding its capabilities for the development and manufacture of new modalities. A $50 million investment at the company’s site in Devens, Massachusetts, adds 9,000 square feet, including a new state-of-the-art process development laboratory and two current Good Manufacturing Practice (cGMP) suites. Now halfway to completion, this project will equip Veranova with greater capabilities for the development and production of HPAPIs, ADC linker-payloads, and other complex molecules critical to next-generation therapeutics.
Veranova is also establishing state-of-the-art bioconjugation development and cGMP manufacturing capabilities at the Devens site. By strengthening U.S.-based infrastructure for ADCs and bioconjugates, Veranova is providing customers with the advanced capabilities and greater supply chain security they need to serve their patients.
Read more about this strategic investment and check out the videos showing the exciting progress of this important expansion.
You can learn more about all of Veranova’s capabilities for new and complex modalities—ADCs, proteolysis targeting chimeras (PROTACs), oligonucleotides, polyethylene glycol (PEG) derivatives, and HPAPIs—at www.veranova.com.
